In addition, promoted BHLHE40 switches off the IL-10 inflammatory “brake” and stimulates the proliferation of (tumor) tissue-infiltrating lymphocytes and inhibits antiviral THαβ cells, which are driven by IL-10 and IFNα/β. Here, IFNA1 is linked to neoplasm.